TerminatedPhase 3

Treatment of Strongyloides Infection

Stopped: The original study PI passed away. Primary and Study Completion dates revised to reflect last participant examination date.

United States51 participantsStarted 2012-05

Plain-language summary

The aim of this study is to evaluate the serologic response in patients with S. stercoralis infection after treatment with a regimen of two single doses of 200 µg/kg of ivermectin given 2 weeks apart versus a regimen of two single doses of 200 µg/kg of ivermectin given in two consecutive days.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * At least 18 years of age * Positive for Strongyloides serology infection (as determined by ELISA) Exclusion Criteria: * Severe intestinal Strongyloides infection * Disseminated Strongyloidiasis infection * Pregnant and breastfeeding women * HTLV-1 co-infection * Patients with indeterminate results on Strongyloides serology * Patients who are immunosuppressed * Unable to read and understand consent form

What they're measuring

Level of Strongyloides Serology as Measured by ELISA at 3-4 Months Post-treatment

Timeframe: 3-4 months post treatment

Level of Strongyloides Serology as Measured by ELISA at 6-8 Months Post-treatment

Timeframe: 6-8 months post treatment

Level of Strongyloides Serology as Measured by ELISA at 9-12 Months Post-treatment

Timeframe: 9-12 months post treatment

Trial details

NCT IDNCT03605758

SponsorAlbert Einstein College of Medicine

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2015-02-05

Results submitted2023-11-02

View on ClinicalTrials.gov More Strongyloides Stercoralis Infection trials